论文部分内容阅读
目的探讨老年急性髓细胞性白血病(AML)的生物靶向药物治疗方法。方法报道1例老年 AML 患者经吉妥单抗治疗的疗效,分析治疗过程并复习相关文献。结果患者因面色苍白,全身乏力2个月,加重1周入院,经骨髓、细胞免疫表型流式细胞术分析诊断为 AML。给予吉妥单抗治疗后达到完全缓解。其后给予多次复查骨髓、血象均正常,无病生存时间15个月。结论老年 AML 患者常规化疗存在风险高,缓解率低,生存期短等不利情况,该例患者经吉妥单抗治疗后获得长时间临床完全缓解,为今后治疗提供了一种有效的方法。
Objective To investigate the bio-targeted drug therapy for senile acute myeloid leukemia (AML). Methods The efficacy of gemtuzumab in one elderly AML patient was reported. The course of treatment was reviewed and relevant literature was reviewed. Results The patient was pale, malaise for 2 months, admitted to hospital for 1 week, and was diagnosed as AML by bone marrow and cellular immunophenotyping. Gemtuzumab was given complete remission after treatment. After giving repeated review of bone marrow, blood were normal, disease-free survival time of 15 months. Conclusion In elderly patients with AML, conventional chemotherapy has the disadvantages of high risk, low response rate, short survival period and so on. The patient with gemcitabine has long-term clinical complete remission, which provides an effective method for future treatment.